Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 5/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976134 | 0.86 | FADS1 (0.57) | FADS1GRM2 | |
| Ethylamine SCHEMBL4974176 | 0.84 | FADS1 (0.52) | FADS1GRM2MAOB | |
| SCHEMBL2894128 | 0.83 | GRM2 (0.50) | FADS1GRM2 | |
| SCHEMBL27739540 | 0.81 | KDM1A (0.39) | POLBKDM1AMAOBMAOAMEN1 | |
| SCHEMBL4974178 | 0.80 | FADS1 (0.48) | FADS1GRM2 | |
| SCHEMBL4977837 | 0.80 | FADS1 (0.58) | FADS1GRM2 | |
| SCHEMBL2900150 | 0.78 | GRM2 (0.48) | FADS1POLBGRM2MEN1KMT2A | |
| SCHEMBL2900149 | 0.78 | GRM2 (0.48) | FADS1POLBGRM2MEN1KMT2A | |
| SCHEMBL27759930 | 0.77 | FADS1 (0.57) | FADS1GRM2 | |
| SCHEMBL2893564 | 0.76 | POLB (0.55) | FADS1POLBGRM2NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | FADS1 4353/4885POLB 3048/4885KDM1A 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.